3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Interventions
rozanolixizumab
7
zilucoplan
6
efgartigimod alfa
5
eculizumab
4
telitacicept
3
ravulizumab
3
Tacrolimus
3
Rituximab
3
Amifampridine
3
Prednisone
2
Mycophenolic Acid
2
HBM9161
2
satralizumab
1
remibrutinib
1
iptacopan
1
inebilizumab
1
Thymectomy
1
Sugars
1
Steroids
1
Sodium Chloride
1
Pyridostigmine Bromide
1
Prednisolone
1
Plasmapheresis
1
Leflunomide
1
Immunoglobulins, Intravenous
1
Hizentra
1
Cladribine
1
Azathioprine
1
Alkalies
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Myasthenia Gravis
×
remibrutinib
×
Clear all
NCT06744920
2026-06-01
RELIEVE
Novartis
Phase 3
Recruiting
180 enrolled